A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study

En Chen; Tao Zhou; Li Liu; Cong Liu; Ming Lei; Hong Tang

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study

Author(s):

En Qiang Chen¹,

Tao You Zhou¹,

Li Liu¹,

Cong Liu¹,

Ming Lei¹,

Hong Tang^2,*

1Center of Infectious Diseases, West China Hospital, Sichuan University, China

2Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, htang6198@hotmail.com, China

Hepatitis Monthly:Vol. 11, issue 1; 27-31

Published online:Jan 31, 2011

Article type:Research Article

Received:Jun 28, 2010

Accepted:Oct 01, 2010

How to Cite:Chen E Q, Zhou T Y, Liu L, Liu C, Lei M, et al. A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study.Hepat Mon.2011;11(1):27-31.

Abstract

Background: The reduction of hepatitis B virus replication to minimal levels is emerging as key therapeutic goal in chronic hepatitis B (CHB).
Objectives: This study aimed to evaluate and compare the efficacies of adefovir (ADV) and entecavir (ETV) in CHB.
Patients and Methods: In this prospective study, 100 naïve patients were assigned to treatment with ADV (33 HBeAg-positive and 19 HBeAg-negative patients) or ETV (32 HBeAg-positive and 16 HBeAg-negative patients). The primary efficacy outcome was ALT normalization, reduction in HBV DNA, and seroconversion of HBeAg. Second efficacy outcomes included resistance and safety. Comparisons of quantitative and qualitative variables between groups were analyzed by student t-test and chi-square test (or Fisher's exact test), respectively.
Results: Among HBeAg-positive patients, ETV was superior to ADV with respect to mean reduction in HBV DNA (-7.5 versus -6.3, respectively, at Month 24, p=0.003) and the percentage of those with HBV DNA<103 copies/mL at Month 24 [96.9% (31/32) vs. 69.7% (23/33), respectively, p=0.002] and <300 copies/mL at Month 24 [84.4% (27/32) vs. 54.5% (18/33), respectively, p=0.004]. But, the rates of ALT normalization and HBeAg seroconversion between the groups were similar [87.9% (29/33) vs. 96.9% (31/32), respectively, p=0.355; and 24.2% (8/33) vs. 25.0% (8/32), respectively, p=0.943]. In HBeAg-negative patients who received ETV or ADV, the reduction in HBV DNA (-6.8 versus -5.9, respectively, p=0.192), percentage of ALT normalization [100% (16/16) vs. 78.9% (15/19), respectively, p=0.109], HBV DNA<103 copies/mL [100% (16/16) vs. 89.5% (17/19), respectively, p=0.489], and HBV DNA <300 copies/mL [100% (16/16) vs. 84.2% (16/19), respectively, p=0.234] were similar. No ETV- or ADV-associated mutations were observed, and both agents were well tolerated.
Conclusions: ETV and ADV are effective therapies for CHB. In HBeAg-positive patients, the efficacy of ETV is significantly superior to that of ADV, and in HBeAg-negative patients, the agents effect similar biochemical and virological responses.

Implication for Health policy/practice/research/medical education:
Authors studied the effects of some oral antiviral medications in treatment of chronic hepatitis B virus. This article is an interesting article for those clinicians involved in the management of CHB patients.
Please cite this paper as:
Chen EQ, Zhou TY, Liu L, Liu C, Lei M, Tang H. A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study. Hepat Mon. 2011;11(1):27-31.

Keywords

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 4 days ago
Scopus by Title: 12
Last Update: 4 days ago
Scopus by Title (Ref): 12
Last Update: 4 days ago
CrossRef: 0
Last Update: 5 days ago

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

En Chen:[PubMed][Scholar]
Tao Zhou:[PubMed][Scholar]
Li Liu:[PubMed][Scholar]
Cong Liu:[PubMed][Scholar]
Ming Lei:[PubMed][Scholar]
Hong Tang:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study

Abstract

Full Text

Last Update: 4 days ago

Last Update: 4 days ago

Last Update: 4 days ago

Last Update: 5 days ago